Erasca Overview

  • Founded
  • 2018
Founded
  • Status
  • Private
  • Employees
  • 53
Employees
  • Latest Deal Type
  • Series B2
  • Latest Deal Amount
  • $120M
Latest Deal Amount
  • Investors
  • 16

Erasca General Information

Description

Developer of oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations, providing patients with new potential solutions to not just treat but cure cancer.

Contact Information

Website
www.erasca.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 10835 Road to the Cure
  • Suite 140
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Erasca Timeline

201920202021
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Erasca Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B2) 20-Jan-2021 $120M 00000 Completed Startup
2. Early Stage VC (Series B) 31-Aug-2020 00000 00000 00000 Completed Startup
1. Early Stage VC (Series A) 05-Mar-2019 $64M $64M 0000 Completed Startup
To view Erasca’s complete valuation and funding history, request access »

Erasca Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-2 00,000,000 00.000000 00.0 00.0 00 00.0 0.000
Series B-1 00,000,000 00.000000 00 00 00 00 00.000
Series A 68,103,681 $0.000100 $1.67 $1.67 1x $1.67 54.57%
To view Erasca’s complete cap table history, request access »

Erasca Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of oncology drugs intended to provide precision oncology options. The company's drugs are being developed thro
Drug Discovery
San Diego, CA
53 As of 2021
00000
00000000000 00000

00000000

aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cill
0000 000000000
San Carlos, CA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

00000000

it, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Erasca Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apexigen Venture Capital-Backed San Carlos, CA 00 00000 00000000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000000 00000000 Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
000000 00000000000 Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
You’re viewing 5 of 30 competitors. Get the full list »

Erasca Executive Team (7)

Name Title Board Seat Contact Info
David Chacko MD Chief Financial Officer
David Luo Vice President, Clinical Research and Operations
Bao Truong Vice President, Regulatory Affairs
Wei Lin MD Chief Medical Officer
Jonathan Lim MD Co-Founder, Chief Executive Officer & Chairman
You’re viewing 5 of 7 executive team members. Get the full list »

Erasca Board Members (8)

Name Representing Role Since
Alexander Casdin Self Board Member 000 0000
Bihua Chen Erasca Board Member 000 0000
James Bristol Ph.D Self Board Member 000 0000
Jonathan Lim MD Self Co-Founder, Chief Executive Officer & Chairman 000 0000
Julie Hambleton MD Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Erasca Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Erasca Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
PFM Health Sciences Venture Capital Minority 000 0000 000000 0
EDBI Venture Capital Minority 000 0000 000000 0
Evolution VC Partners Venture Capital Minority 000 0000 000000 0
Hillhouse Capital Group PE/Buyout Minority 000 0000 000000 0
OrbiMed PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »